-
Electronic (PDF)
-
Site License
-
Enterprisewide
National Jewish Health - Developmental Therapeutics Review - Q4 2010
Global Markets Direct, December 2010, Pages: 24
National Jewish Health – Developmental Therapeutics Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “National Jewish Health – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by National Jewish Health.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Jewish Health with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of National Jewish Health’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Review of therapeutics under development by National Jewish Health.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Jewish Health with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of National Jewish Health’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
List of Tables
List of Figures
National Jewish Health Snapshot
National Jewish Health Overview
Key Information
Key Facts
National Jewish Health – Research and Development Overview
Key Therapeutic Areas
National Jewish Health – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
National Jewish Health – Pipeline Products Glance
National Jewish Health Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
National Jewish Health – Drug Profiles
Lovastatin
Product Description
Mechanism of Action
R&D Progress
Mesalamine
Product Description
Mechanism of Action
R&D Progress
Sildenafil
Product Description
Mechanism of Action
R&D Progress
Xolair
Product Description
Mechanism of Action
R&D Progress
National Jewish Health – Pipeline Analysis
National Jewish Health – Pipeline Products by Therapeutic Class
National Jewish Health Pipeline Products By Target
National Jewish Health – Pipeline Products by Route of Administration
National Jewish Health – Pipeline Products by Molecule Type
National Jewish Health – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
National Jewish Health, Deals Summary, 2004 to 2010
National Jewish Health Detailed Deal Summary
InterMune Announces Co-Development Agreement With National Jewish Health
National Jewish Health Enters Into An Agreement With LabCorp
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
